MX2020005213A - Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. - Google Patents

Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Info

Publication number
MX2020005213A
MX2020005213A MX2020005213A MX2020005213A MX2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A
Authority
MX
Mexico
Prior art keywords
inhibitors
compositions
methods
same
present
Prior art date
Application number
MX2020005213A
Other languages
English (en)
Inventor
Russell C Petter
Deqiang Niu
Matthew David Alexander
Joseph John Mcdonald
Yike Ni
Juswinder Singh
Claudio Chuaqui
John Malona
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2020005213A publication Critical patent/MX2020005213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

La presente invención proporciona compuestos, composiciones de los mismos y métodos para utilizarlos.
MX2020005213A 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. MX2020005213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
MX2020005213A true MX2020005213A (es) 2020-08-20

Family

ID=55454109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003359A MX2017003359A (es) 2014-09-17 2015-09-16 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2020005213A MX2020005213A (es) 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017003359A MX2017003359A (es) 2014-09-17 2015-09-16 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Country Status (30)

Country Link
US (5) US9458175B2 (es)
EP (2) EP3912981A1 (es)
JP (3) JP6556225B2 (es)
KR (1) KR102457848B1 (es)
CN (1) CN106998692B (es)
AU (1) AU2015317741B2 (es)
BR (1) BR112017005266B1 (es)
CA (1) CA2961607C (es)
CL (1) CL2017000576A1 (es)
CO (1) CO2017003279A2 (es)
CY (1) CY1124215T1 (es)
DK (1) DK3193611T3 (es)
EA (1) EA037299B1 (es)
EC (1) ECSP17023281A (es)
ES (1) ES2874561T3 (es)
HR (1) HRP20210529T1 (es)
HU (1) HUE054347T2 (es)
IL (1) IL251051B (es)
LT (1) LT3193611T (es)
MA (1) MA40534B1 (es)
MX (2) MX2017003359A (es)
NZ (1) NZ730603A (es)
PL (1) PL3193611T3 (es)
PT (1) PT3193611T (es)
RS (1) RS62017B1 (es)
SA (1) SA517381115B1 (es)
SG (2) SG10201902326XA (es)
SI (1) SI3193611T1 (es)
TW (1) TWI744217B (es)
WO (1) WO2016044463A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
JP6556225B2 (ja) 2014-09-17 2019-08-07 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤およびその使用
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
JP2020514360A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
EP3596086A4 (en) * 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREFORE
EP3596083A4 (en) * 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
JP2023513797A (ja) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２阻害剤による単剤療法および併用療法
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University St Louis COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
US20230255979A1 (en) * 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA201000100A1 (ru) 2007-07-16 2010-08-30 Новартис Аг Гетероциклические соединения, полезные в качестве ингибиторов mk2
EP2217596B8 (en) 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
JP6396216B2 (ja) 2012-02-22 2018-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶媒体
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
PE20151253A1 (es) * 2012-09-24 2015-10-04 Claremont Speede Metodo y sistema de acceso a datos y eliminacion de datos controlados por emisor movil
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
JP6556225B2 (ja) 2014-09-17 2019-08-07 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤およびその使用
AU2016205125A1 (en) 2015-01-08 2017-07-13 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
JP2020514360A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREFORE
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
CN106998692B (zh) 2020-09-08
SI3193611T1 (sl) 2021-08-31
CL2017000576A1 (es) 2017-12-01
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
EP3193611A4 (en) 2018-02-28
EA037299B1 (ru) 2021-03-05
TW201617351A (zh) 2016-05-16
RS62017B1 (sr) 2021-07-30
JP7375072B2 (ja) 2023-11-07
US20190375762A1 (en) 2019-12-12
US11584757B2 (en) 2023-02-21
US10577380B2 (en) 2020-03-03
LT3193611T (lt) 2021-08-25
SA517381115B1 (ar) 2021-03-09
WO2016044463A2 (en) 2016-03-24
US20210053984A1 (en) 2021-02-25
US20160075720A1 (en) 2016-03-17
IL251051A0 (en) 2017-04-30
CA2961607C (en) 2023-03-28
SG10201902326XA (en) 2019-04-29
PL3193611T3 (pl) 2021-10-04
ECSP17023281A (es) 2017-06-30
CN106998692A (zh) 2017-08-01
NZ730603A (en) 2024-02-23
US9790235B2 (en) 2017-10-17
CA2961607A1 (en) 2016-03-24
JP6556225B2 (ja) 2019-08-07
WO2016044463A3 (en) 2016-09-01
AU2015317741B2 (en) 2020-01-16
JP2017529367A (ja) 2017-10-05
EP3912981A1 (en) 2021-11-24
EP3193611A2 (en) 2017-07-26
EA201790380A1 (ru) 2017-08-31
MX2017003359A (es) 2017-11-22
HUE054347T2 (hu) 2021-08-30
JP2022078315A (ja) 2022-05-24
US9458175B2 (en) 2016-10-04
PT3193611T (pt) 2021-05-28
SG11201701861RA (en) 2017-04-27
IL251051B (en) 2019-11-28
MA40534B1 (fr) 2021-04-30
EP3193611B1 (en) 2021-03-24
TWI744217B (zh) 2021-11-01
US10253040B1 (en) 2019-04-09
US20170114073A1 (en) 2017-04-27
JP2019194236A (ja) 2019-11-07
CO2017003279A2 (es) 2017-09-29
CY1124215T1 (el) 2022-05-27
MA40534A (fr) 2016-03-24
KR20170063734A (ko) 2017-06-08
AU2015317741A1 (en) 2017-04-20
BR112017005266A2 (pt) 2017-12-12
DK3193611T3 (da) 2021-05-10
KR102457848B1 (ko) 2022-10-25
BR112017005266B1 (pt) 2022-11-01

Similar Documents

Publication Publication Date Title
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2018003491A (es) Represores de htt y usos de estos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
PH12016502213A1 (en) Novel compositions, uses and methods for making them
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
PH12017501864A1 (en) Compositions and methods for treating autism
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
TW201613892A (en) Forms and compositions of an ERK inhibitor